Dulaglutide Clinical Trials (2026): 89 Studies for Type 2 Diabetes & Diabetes Mellitus, Type 2
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
89 Dulaglutide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 35 indications (including Type 2 Diabetes & Diabetes Mellitus, Type 2) and 1,405,695 total planned enrollment. 23 Phase 3 Dulaglutide trials and 17 Phase 2, 19 Phase 4 are listed. 8 Dulaglutide clinical trials are actively recruiting at 38 U.S. sites across 24 states. Most recent activity: NCT07282041 (Dec 2030).
Where to Participate: All Dulaglutide Trial Sites in the U.S. (38 sites across 24 states)
Every actively recruiting Dulaglutidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | University of Arizona | Tucson85724 | NCT06739122 | Map |
| AR | Arkansas Childrens Hospital | Little Rock72202-3500 | NCT06739122 | Map |
| CA | Division of Endocrinology, Diabetes, and Metabolism | Los Angeles90027 | NCT06739122 | Map |
| CA | UCLA Mattel Children's Hospital | Los Angeles90095 | NCT06739122 | Map |
| CA | University of California, San Francisco | San Francisco94158 | NCT06739122 | Map |
| CO | Children's Hospital of Colorado | Aurora80045 | NCT04731272 | Map |
| CT | Yale Diabetes Research | New Haven06511 | NCT06739122 | Map |
| DC | Emerson Clinical Research Institute | Washington D.C.20009 | NCT06739122 | Map |
| FL | Nemours Children's Health | Jacksonville32207 | NCT06739122 | Map |
| FL | D&H National Research Centers, Inc | Miami33155 | NCT06739122 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT06739122 | Map |
| FL | D&H Tamarac Research Center, LLC | Tamarac33321 | NCT06739122 | Map |
| FL | University of South Florida | Tampa33612 | NCT06739122 | Map |
| GA | Children's Healthcare of Atlanta - Center for Advanced Pediatrics | Atlanta30329 | NCT06739122 | Map |
| GA | Centricity Research Columbus Endocrinology | Columbus31904 | NCT06739122 | Map |
| ID | St. Luke's Children's Endocrinology and Diabetes | Boise83712 | NCT06739122 | Map |
| IL | University of Illinois at Chicago | Chicago60612 | NCT06739122 | Map |
| IA | University of Iowa Stead Family Children's Hospitals | Iowa City52242 | NCT06739122 | Map |
| KY | Norton Children's Endocrinology | Louisville40202 | NCT06739122 | Map |
| MD | Johns Hopkins University School of Medicine | Baltimore21287 | NCT06739122 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT06739122 | Map |
| NM | University of New Mexico Hospital | Albuquerque87106 | NCT06739122 | Map |
| NY | WBMD Pediatrics | Buffalo14203 | NCT06739122 | Map |
| NY | Cohen Children's Medical Center Division of Pediatric Endocrinology | Hyde Park11042 | NCT06739122 | Map |
| NY | SUNY Upstate Medical University | Syracuse13210 | NCT06739122 | Map |
| NC | UNC Children's Hospital | Chapel Hill27514 | NCT06739122 | Map |
| OH | Childrens Hospital Medical Center | Cincinnati45229 | NCT06739122 | Map |
| OH | Cleveland Clinic Childrens Outpatient Center | Cleveland44106 | NCT06739122 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06739122 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06739122 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT04731272 | Map |
| SC | Prisma Health Pediatric Endocrinology | Columbia29203 | NCT06739122 | Map |
| SC | Prisma Health Midlands | Greenville29615 | NCT06739122 | Map |
| TX | Research Institute of Dallas | Dallas75231 | NCT06739122 | Map |
| TX | Texas Childrens Hospital | Houston77030 | NCT06739122 | Map |
| TX | UT Health Houston | Houston77030 | NCT06739122 | Map |
| UT | University of Utah | Salt Lake City84112 | NCT06739122 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT06739122 | Map |
Dulaglutide clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | suspended | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 1 | 14 | 15 | ||||||
| P1/P2 | 1 | 1 | 2 | ||||||
| P2 | 2 | 13 | 1 | 1 | 17 | ||||
| P2/P3 | 1 | 1 | |||||||
| P3 | 1 | 1 | 19 | 1 | 1 | 23 | |||
| P4 | 1 | 1 | 9 | 2 | 1 | 5 | 19 | ||
| N/A | 3 | 8 | 1 | 12 |
Recruiting Dulaglutide clinical trials (8)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07282041 | RADIANTRole of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis | P2/P3 | Intracranial Atherosclerosis | 130 | Dec 2025 |
| NCT06324461 | GLUMINSGLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery | P4 | Myocardial Injury | 372 | Mar 2024 |
| NCT04731272 | GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance | P2 | Cystic Fibrosis | 30 | Jul 2021 |
| NCT06739122 | LY2189265A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | P3 | Type 2 Diabetes | 55 | Jan 2025 |
| NCT07537088 | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | P4 | T2DM (Type 2 Diabetes Mellitus) | 468 | May 2026 |
| NCT07156539 | A Phase 3 Study of HS-20094 in Patients With T2DM | P3 | Type 2 Diabetes | 546 | Sep 2025 |
| NCT07319286 | Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus | P1/P2 | Menstrual Irregularities | 50 | Aug 2025 |
| NCT07109700 | A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin | P2 | Type 2 Diabetes | 216 | Apr 2025 |
Dulaglutide clinical trials by indication
Type 2 Diabetes (23)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06739122 | LY2189265 | P3 | recruiting | A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) |
| NCT07156539 | — | P3 | not yet recruiting | A Phase 3 Study of HS-20094 in Patients With T2DM |
| NCT07417631 | — | N/A | active not recruiting | Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data. |
| NCT07417618 | INTERCEPT | N/A | active not recruiting | INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) |
| NCT06779929 | SURPASS CVOT | N/A | completed | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes |
| NCT07109700 | — | P2 | recruiting | A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin |
| NCT07088718 | DUP-SURPASS | N/A | completed | Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data |
| NCT07096063 | TIRZSEMA-CVOT | N/A | completed | Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk |
| + 15 more, see All trials below. | ||||
Diabetes Mellitus, Type 2 (17)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03648554 | REALIST | P4 | unknown | Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) |
| NCT05659537 | LY2189265 | P4 | completed | A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India |
| NCT05407961 | — | P1 | completed | A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus |
| NCT05005741 | — | P4 | unknown | The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. |
| NCT05377333 | LY2189265 | P1 | completed | A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes |
| NCT05516966 | — | P1 | completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus |
| NCT03444142 | — | P4 | unknown | Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes |
| NCT04515576 | — | P1 | completed | A Study of LY3493269 in Participants With Type 2 Diabetes |
| + 9 more, see All trials below. | ||||
Type 2 Diabetes Mellitus (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06235086 | — | P3 | completed | A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus |
| NCT04255433 | SURPASS-CVOT | P3 | completed | A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes |
| NCT05348122 | — | P2 | unknown | A Study of TG103 Injection in Type 2 Diabetes Subjects |
| NCT04893148 | — | P4 | unknown | Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes |
| NCT04591626 | AWARD-CHN3 | P3 | completed | A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes |
| NCT03684642 | AMPLITUDE-D | P3 | terminated | Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin |
| NCT02787551 | LixiLan-G | P3 | completed | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period |
| NCT03131687 | LY3298176 | P2 | completed | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus |
| + 4 more, see All trials below. | ||||
Diabetes Mellitus (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05218915 | — | P4 | completed | Basal Plus GLP1-ra on Glycemic Variability in CKD |
| NCT04809220 | AWARD-JPN | P3 | completed | A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes |
| NCT03824002 | — | P4 | completed | Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables |
Healthy (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04641312 | — | P1 | completed | A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes |
| NCT03363906 | — | P1 | completed | A Study of Dulaglutide in Healthy Participants |
| NCT02759107 | LY3298176 | P1 | completed | A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) |
Diabetes (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03015220 | PIONEER 10 | P3 | completed | Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes |
| NCT02648204 | SUSTAIN 7 | P3 | completed | Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. |
T2DM (Type 2 Diabetes Mellitus) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07537088 | — | P4 | not yet recruiting | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease |
Type 2 Diabetes Mellitus (T2DM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07313813 | GBGT | P1 | active not recruiting | A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus |
Intracranial Atherosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07282041 | RADIANT | P2/P3 | recruiting | Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis |
Menstrual Irregularities (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07319286 | — | P1/P2 | enrolling by invitation | Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus |
Diabetes Mellitus Type 2 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06851962 | EPHIC-DIA2 | P4 | active not recruiting | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. |
Transfusion Dependent Beta Thalassemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07370922 | — | P2 | completed | Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia |
Type2 Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06257966 | — | P3 | active not recruiting | A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin |
Myocardial Injury (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06324461 | GLUMINS | P4 | recruiting | GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery |
Metabolic-associated Fatty Liver Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05140694 | — | P4 | unknown | Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D |
Diabetes Mellitus, Type 1 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05478707 | KML002 | P2 | suspended | Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes |
Bipolar Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06331286 | — | N/A | unknown | The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity |
T2DM (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05680129 | — | P3 | completed | A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM |
Chronic Kidney Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05254418 | GLIMP | P2 | completed | Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease |
Type 2 Diabetic Nephropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06182891 | — | N/A | completed | Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy |
Hyperglycemia Stress (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04862234 | — | P4 | terminated | Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients |
Cystic Fibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04731272 | — | P2 | recruiting | GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance |
Sexual Functioning (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04687514 | DESIRE | P2 | completed | Effects of Glucagon-Like Peptide-1 Analogs on Sexuality |
Glucose Intolerance (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04387201 | — | P4 | completed | GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response |
Type 2 Diabetes Treated With Insulin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04829903 | — | N/A | completed | Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04189848 | — | P4 | completed | Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc |
Stress Hyperglycemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03743025 | — | P4 | terminated | Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients |
Adult Subjects With Type1Diabetes and Insulin Microsecretion (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03668470 | DIAMOND GLP1 | P2 | completed | Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes |
Non Alcoholic Fatty Liver Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03590626 | D-LIFT | N/A | completed | Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease |
Non-Alcoholic Fatty Liver Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05946148 | NAMELS-18 | N/A | completed | Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18) |
Urine Albumin (UAlb) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06611904 | — | N/A | active not recruiting | The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria |
Glucagon-like Peptide-1 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03204396 | SKIP | P2 | completed | Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues |
Thirst (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03141632 | GATE | P2 | completed | Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake |
Primary Polydipsia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02770885 | GOLD | P2 | completed | Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study) |
Cardiovascular Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01394952 | REWIND | P3 | completed | Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
Dulaglutide pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| GLUMINS | NCT06324461 | P4 | recruiting | Myocardial Injury | 372 | — |
| EPHIC-DIA2 | NCT06851962 | P4 | active not recruiting | Diabetes Mellitus Type 2 | 504 | — |
| SURPASS-SWITCH | NCT05564039 | P4 | completed | Type 2 Diabetes | 282 | PMID 41912265 |
| REALIST | NCT03648554 | P4 | unknown | Diabetes Mellitus, Type 2 | 93 | — |
| LY2189265 | NCT05659537 | P4 | completed | Diabetes Mellitus, Type 2 | 212 | — |
| LY2189265 | NCT03315780 | P4 | completed | Type 2 Diabetes | 12 | PMID 30949907 |
| LY2189265 | NCT06739122 | P3 | recruiting | Type 2 Diabetes | 55 | — |
| SURPASS-CVOT | NCT04255433 | P3 | completed | Type 2 Diabetes Mellitus | 13,299 | PMID 41903177 |
| AWARD-JPN | NCT04809220 | P3 | completed | Diabetes Mellitus | 591 | — |
| AWARD-CHN3 | NCT04591626 | P3 | completed | Type 2 Diabetes Mellitus | 291 | — |
| AWARD-PEDS | NCT02963766 | P3 | completed | Type 2 Diabetes | 154 | PMID 35658022 |
| SURPASS J-mono | NCT03861052 | P3 | completed | Type 2 Diabetes | 636 | PMID 35210595 |
| AMPLITUDE-D | NCT03684642 | P3 | terminated | Type 2 Diabetes Mellitus | 908 | — |
| AWARD-11 | NCT03495102 | P3 | completed | Diabetes Mellitus, Type 2 | 1,842 | PMID 33397768 |
| LixiLan-G | NCT02787551 | P3 | completed | Type 2 Diabetes Mellitus | 514 | PMID 35332216 |
| REWIND | NCT01394952 | P3 | completed | Cardiovascular Disease | 9,901 | PMID 29693361 |
| PIONEER 10 | NCT03015220 | P3 | completed | Diabetes | 458 | PMID 32333876 |
| SUSTAIN 7 | NCT02648204 | P3 | completed | Diabetes | 1,201 | PMID 29557057 |
| AWARD-10 | NCT02597049 | P3 | completed | Type 2 Diabetes Mellitus | 424 | PMID 29483060 |
| AWARD-7 | NCT01621178 | P3 | completed | Type 2 Diabetes | 577 | PMID 29910024 |
| AWARD-9 | NCT02152371 | P3 | completed | Diabetes Mellitus, Type 2 | 300 | PMID 29110972 |
| AWARD-8 | NCT01769378 | P3 | completed | Type 2 Diabetes Mellitus | 300 | — |
| AWARD-CHN2 | NCT01648582 | P3 | completed | Type 2 Diabetes Mellitus | 774 | PMID 34453682 |
| AWARD-CHN1 | NCT01644500 | P3 | completed | Type 2 Diabetes Mellitus | 737 | PMID 32277401 |
| KML002 | NCT05478707 | P2 | suspended | Diabetes Mellitus, Type 1 | 47 | PMID 26265791 |
| GLIMP | NCT05254418 | P2 | completed | Chronic Kidney Diseases | 7 | — |
| DESIRE | NCT04687514 | P2 | completed | Sexual Functioning | 26 | — |
| SKIP | NCT03204396 | P2 | completed | Glucagon-like Peptide-1 | 256 | PMID 37991022 |
| DIAMOND GLP1 | NCT03668470 | P2 | completed | Adult Subjects With Type1Diabetes and Insulin Microsecretion | 45 | — |
| GOLD | NCT02770885 | P2 | completed | Primary Polydipsia | 50 | PMID 34473645 |
| LY3298176 | NCT03131687 | P2 | completed | Type 2 Diabetes Mellitus | 318 | PMID 34608929 |
| GATE | NCT03141632 | P2 | completed | Thirst | 17 | — |
Terminated and withdrawn Dulaglutide trials (4)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05478707suspendedTherapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
- NCT04862234terminatedPerioperative Stress Hyperglycemia in General and Vascular Surgery Patients
- NCT03743025terminatedMetabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
- NCT03684642terminatedEfficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
All Dulaglutide trials (89)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07282041 | RADIANT | Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis | P2/P3 | recruiting | 130 | National University of Singapore | Dec 2025 |
| NCT06324461 | GLUMINS | GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery | P4 | recruiting | 372 | The University of Hong Kong | Mar 2024 |
| NCT05478707 | KML002 | Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes | P2 | suspended | 47 | University of Virginia | Oct 2023 |
| NCT04731272 | GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance | P2 | recruiting | 30 | University of Pennsylvania | Jul 2021 | |
| NCT06739122 | LY2189265 | A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | P3 | recruiting | 55 | Eli Lilly and Company | Jan 2025 |
| NCT07537088 | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | P4 | not yet recruiting | 468 | First Affiliated Hospital of Wannan Medical College | May 2026 | |
| NCT07156539 | A Phase 3 Study of HS-20094 in Patients With T2DM | P3 | not yet recruiting | 546 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Sep 2025 | |
| NCT07319286 | Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus | P1/P2 | enrolling by invitation | 50 | Ain Shams University | Aug 2025 | |
| NCT06257966 | A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin | P3 | active not recruiting | 600 | Beijing Dongfang Biotech Co., Ltd. | Jul 2024 | |
| NCT07313813 | GBGT | A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus | P1 | active not recruiting | 20 | Eli Lilly and Company | Dec 2025 |
| NCT06851962 | EPHIC-DIA2 | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. | P4 | active not recruiting | 504 | Fundación para la Investigación del Hospital Clínico de Valencia | May 2025 |
| NCT07417631 | Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data. | — | active not recruiting | 300,000 | Brigham and Women's Hospital | Feb 2026 | |
| NCT07417618 | INTERCEPT | INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | — | active not recruiting | 60,000 | Brigham and Women's Hospital | Jan 2026 |
| NCT06779929 | SURPASS CVOT | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | — | completed | 70,000 | Brigham and Women's Hospital | Nov 2024 |
| NCT07109700 | A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin | P2 | recruiting | 216 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Apr 2025 | |
| NCT06235086 | A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus | P3 | completed | 632 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Apr 2024 | |
| NCT07370922 | Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia | P2 | completed | 80 | Ain Shams University | Nov 2024 | |
| NCT05140694 | Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D | P4 | unknown | 135 | Seoul National University Bundang Hospital | Dec 2023 | |
| NCT07088718 | DUP-SURPASS | Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data | — | completed | 44,671 | Brigham and Women's Hospital | Oct 2024 |
| NCT07096063 | TIRZSEMA-CVOT | Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | — | completed | 887,132 | Brigham and Women's Hospital | Oct 2024 |
| NCT04255433 | SURPASS-CVOT | A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | P3 | completed | 13,299 | Eli Lilly and Company | May 2020 |
| NCT06148649 | Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus | P2 | completed | 234 | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Dec 2023 | |
| NCT06901648 | A Study of HS-20094 in Patients With T2DM | P2 | completed | 275 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Feb 2024 | |
| NCT06331286 | The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity | N/A | unknown | 60 | First Affiliated Hospital of Zhejiang University | Sep 2023 | |
| NCT06611904 | The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria | N/A | active not recruiting | 60 | Attikon Hospital | Feb 2018 | |
| NCT05218915 | Basal Plus GLP1-ra on Glycemic Variability in CKD | P4 | completed | 95 | Elaine Chow | Jan 2022 | |
| NCT05680129 | A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM | P3 | completed | 623 | Hangzhou Sciwind Biosciences Co., Ltd. | Jan 2023 | |
| NCT05564039 | SURPASS-SWITCH | A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) | P4 | completed | 282 | Eli Lilly and Company | Nov 2022 |
| NCT05254418 | GLIMP | Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease | P2 | completed | 7 | Vanderbilt University Medical Center | Mar 2022 |
| NCT05606913 | A Study of IBI362 in Participants With Type 2 Diabetes | P3 | completed | 731 | Innovent Biologics (Suzhou) Co. Ltd. | Jan 2023 | |
| NCT03648554 | REALIST | Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) | P4 | unknown | 93 | Central Hospital, Nancy, France | Sep 2019 |
| NCT05659537 | LY2189265 | A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India | P4 | completed | 212 | Eli Lilly and Company | Dec 2022 |
| NCT05407961 | A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus | P1 | completed | 90 | Eli Lilly and Company | Jun 2022 | |
| NCT05005741 | The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. | P4 | unknown | 120 | Second Xiangya Hospital of Central South University | May 2021 | |
| NCT05377333 | LY2189265 | A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes | P1 | completed | 94 | Eli Lilly and Company | Jun 2022 |
| NCT05348122 | A Study of TG103 Injection in Type 2 Diabetes Subjects | P2 | unknown | 240 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Jun 2022 | |
| NCT06182891 | Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy | N/A | completed | 300 | The Affiliated Hospital of Xuzhou Medical University | Oct 2021 | |
| NCT04387201 | GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response | P4 | completed | 23 | The University of Texas Health Science Center, Houston | May 2020 | |
| NCT04862234 | Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients | P4 | terminated | 16 | Emory University | Aug 2021 | |
| NCT05516966 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus | P1 | completed | 64 | Fujian Shengdi Pharmaceutical Co., Ltd. | Oct 2022 | |
| NCT03743025 | Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients | P4 | terminated | 28 | Emory University | Mar 2019 | |
| NCT04809220 | AWARD-JPN | A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes | P3 | completed | 591 | Eli Lilly and Company | Apr 2021 |
| NCT04893148 | Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes | P4 | unknown | 40 | Chungbuk National University Hospital | May 2020 | |
| NCT04867785 | A Study of LY3437943 in Participants With Type 2 Diabetes | P2 | completed | 281 | Eli Lilly and Company | May 2021 | |
| NCT05048719 | A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus | P2 | completed | 383 | Eli Lilly and Company | Sep 2021 | |
| NCT04687514 | DESIRE | Effects of Glucagon-Like Peptide-1 Analogs on Sexuality | P2 | completed | 26 | University Hospital, Basel, Switzerland | May 2021 |
| NCT03204396 | SKIP | Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues | P2 | completed | 256 | University Hospital, Basel, Switzerland | Jun 2017 |
| NCT05459285 | A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects | P1 | completed | 68 | Sunshine Lake Pharma Co., Ltd. | May 2022 | |
| NCT04591626 | AWARD-CHN3 | A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes | P3 | completed | 291 | Eli Lilly and Company | Dec 2020 |
| NCT02963766 | AWARD-PEDS | A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | P3 | completed | 154 | Eli Lilly and Company | Dec 2016 |
| NCT04641312 | A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes | P1 | completed | 67 | Eli Lilly and Company | Nov 2020 | |
| NCT03444142 | Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes | P4 | unknown | 30 | University of Guadalajara | Nov 2017 | |
| NCT04829903 | Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin | N/A | completed | 116 | Corporacion Parc Tauli | Jan 2020 | |
| NCT04374578 | DIVE | Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes | — | completed | 100 | Shanghai Zhongshan Hospital | May 2020 |
| NCT05946148 | NAMELS-18 | Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18) | — | completed | 78 | National and Kapodistrian University of Athens | Jun 2018 |
| NCT04466904 | Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM | P1/P2 | completed | 42 | Innovent Biologics (Suzhou) Co. Ltd. | Sep 2020 | |
| NCT03861052 | SURPASS J-mono | A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | P3 | completed | 636 | Eli Lilly and Company | May 2019 |
| NCT04515576 | A Study of LY3493269 in Participants With Type 2 Diabetes | P1 | completed | 56 | Eli Lilly and Company | Aug 2020 | |
| NCT03668470 | DIAMOND GLP1 | Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes | P2 | completed | 45 | Hospices Civils de Lyon | Jan 2019 |
| NCT04143802 | T2DM | A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | P1 | completed | 72 | Eli Lilly and Company | Dec 2019 |
| NCT03684642 | AMPLITUDE-D | Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin | P3 | terminated | 908 | Sanofi | Sep 2018 |
| NCT04189848 | Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc | P4 | completed | 104 | Novo Nordisk A/S | Dec 2019 | |
| NCT03590626 | D-LIFT | Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease | N/A | completed | 60 | Medanta, The Medicity, India | Jan 2019 |
| NCT03495102 | AWARD-11 | A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes | P3 | completed | 1,842 | Eli Lilly and Company | Apr 2018 |
| NCT02770885 | GOLD | Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study) | P2 | completed | 50 | University Hospital, Basel, Switzerland | Mar 2016 |
| NCT03724981 | A Study Comparing the Dulaglutide Pen and the Semaglutide Pen | P4 | completed | 312 | Eli Lilly and Company | Oct 2018 | |
| NCT02787551 | LixiLan-G | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | P3 | completed | 514 | Sanofi | Jul 2016 |
| NCT01394952 | REWIND | Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) | P3 | completed | 9,901 | Eli Lilly and Company | Jul 2011 |
| NCT03131687 | LY3298176 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus | P2 | completed | 318 | Eli Lilly and Company | May 2017 |
| NCT03015220 | PIONEER 10 | Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | P3 | completed | 458 | Novo Nordisk A/S | Jan 2017 |
| NCT02750410 | A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes | P4 | completed | 159 | Eli Lilly and Company | Aug 2016 | |
| NCT03363906 | A Study of Dulaglutide in Healthy Participants | P1 | completed | 27 | Eli Lilly and Company | Dec 2017 | |
| NCT03824002 | Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables | P4 | completed | 92 | University of Palermo | Apr 2017 | |
| NCT03315780 | LY2189265 | A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes | P4 | completed | 12 | Eli Lilly and Company | Oct 2017 |
| NCT02973100 | A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy | P2 | completed | 318 | Eli Lilly and Company | Dec 2016 | |
| NCT02759107 | LY3298176 | A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | P1 | completed | 142 | Eli Lilly and Company | May 2016 |
| NCT02648204 | SUSTAIN 7 | Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | P3 | completed | 1,201 | Novo Nordisk A/S | Jan 2016 |
| NCT03141632 | GATE | Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake | P2 | completed | 17 | University Hospital, Basel, Switzerland | Oct 2016 |
| NCT02597049 | AWARD-10 | A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus | P3 | completed | 424 | Eli Lilly and Company | Nov 2015 |
| NCT01621178 | AWARD-7 | A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) | P3 | completed | 577 | Eli Lilly and Company | Jul 2012 |
| NCT02152371 | AWARD-9 | A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes | P3 | completed | 300 | Eli Lilly and Company | May 2014 |
| NCT01769378 | AWARD-8 | Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) | P3 | completed | 300 | Eli Lilly and Company | Jan 2013 |
| NCT01648582 | AWARD-CHN2 | A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus | P3 | completed | 774 | Eli Lilly and Company | Jul 2012 |
| NCT01644500 | AWARD-CHN1 | A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus | P3 | completed | 737 | Eli Lilly and Company | Jul 2012 |
| NCT01667900 | A Study of Dulaglutide in Chinese Participants | P1 | completed | 58 | Eli Lilly and Company | Aug 2012 | |
| NCT01524770 | A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe | P1 | completed | 50 | Eli Lilly and Company | Mar 2012 | |
| NCT01458210 | A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants | P1 | completed | 22 | Eli Lilly and Company | Oct 2011 | |
| NCT01432938 | A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants | P1 | completed | 28 | Eli Lilly and Company | Sep 2011 | |
| NCT01436201 | A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants | P1 | completed | 24 | Eli Lilly and Company | Sep 2011 |
Dulaglutide clinical trials: frequently asked questions
- How many Dulaglutide clinical trials are there?
- 89 Dulaglutide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 64 are marked completed.
- Are Dulaglutide clinical trials recruiting in 2026?
- Yes — 6 Dulaglutide trials are actively recruiting in 2026, with 38 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Dulaglutide being studied for?
- Dulaglutide is being studied for Type 2 Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus, Healthy, Diabetes and 64 more. The trials are grouped by indication on this page.
- What phase is Dulaglutide in?
- Dulaglutide clinical trials span 19 Phase 4, 23 Phase 3, 17 Phase 2, 15 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Dulaglutide clinical trials?
- The lead sponsor across the most Dulaglutide trials is Eli Lilly and Company, with 38 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Dulaglutideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: